Sermorelin, Hexarelin, and 'Manjaro' stacking claims: what the evidence supports

A recent TikTok video by Dr. Faryal Farooqi presents a rapid-fire overview of peptide stacking, attributing specific benefits to Sermorelin, Hexarelin, and a substance referred to as “Manjaro.” The clip suggests that combining these compounds leads to faster recovery, better energy, and peak performance. While such claims are common in social media wellness content, they often compress complex pharmacology into oversimplified soundbites. This article examines what the research actually says about these peptides and the practice of stacking them.

What the clip is claiming

The video implies that Sermorelin reliably increases growth hormone levels, that Hexarelin directly burns fat and suppresses cravings, and that “Manjaro” (likely a colloquial reference to the GLP-1/GIP agonist tirzepatide, sold under the brand name Mounjaro) helps balance metabolism. The overarching message is that stacking these compounds is a straightforward path to improved body composition and performance.

What the research neighborhood actually covers

Sermorelin is a growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary to release endogenous growth hormone. Clinical studies have shown it can increase GH levels in certain populations, particularly in children with growth hormone deficiency and in some adults with age-related decline. However, its effects on body composition and performance are less robustly documented, and results vary widely based on individual physiology and dosing.

Hexarelin is a synthetic ghrelin mimetic that binds to the ghrelin receptor, stimulating GH release. Preclinical and some human studies suggest it may influence appetite and fat metabolism, but evidence for direct “fat burning” or “craving crushing” in humans is limited. Most data come from animal models or small, short-term trials.

“Manjaro” is not a peptide; it is a brand name for tirzepatide, a dual GIP/GLP-1 receptor agonist used for type 2 diabetes and obesity. Tirzepatide has demonstrated significant effects on weight loss and glycemic control in large clinical trials. However, it is not classified as a research peptide in the same category as Sermorelin or Hexarelin, and its inclusion in a peptide-stacking protocol is unconventional.

Limits, missing context, and what a 15-second clip cannot show

The clip omits critical context: dosing, cycle length, potential side effects, and the fact that most peptide research is in early stages or focused on specific clinical populations. A 15-second video cannot convey that Sermorelin’s GH response is pulsatile and may diminish with chronic use, or that Hexarelin’s effects on appetite are complex and may not translate to sustained fat loss. Furthermore, stacking multiple GH secretagogues can lead to elevated cortisol and prolactin levels, which may cause adverse effects. The clip also fails to mention that tirzepatide is a prescription medication with its own side-effect profile, and combining it with GH peptides has not been studied for safety or efficacy.

How this maps to named research compounds

For researchers exploring these pathways, the catalog includes Sermorelin and Hexarelin as separate compounds, as well as CJC-1295 with and without DAC, Ipamorelin, and GHRP-6, which are often used in comparative studies of GH stimulation. The catalog does not list “Manjaro” or tirzepatide, as it is not a peptide. If the clip intended to refer to a peptide for metabolic balance, compounds like AOD9604 (Fragment 176-191) or Tesamorelin might be more relevant, though they are not mentioned in the clip. The catalog also offers BPC-157 and TB-500 for recovery-focused research, but these are not part of the clip’s claims.

Research-use caveat

All compounds mentioned are intended for laboratory research and investigational purposes only, not for human or veterinary use. Researchers should consult primary literature and adhere to institutional guidelines when designing studies. The claims in the clip are anecdotal and not supported by peer-reviewed evidence for stacking these specific agents.

Open the full video fact-check page (transcript, takeaways, embedded clip).